57591-61-4

Usage

Uses

Used in Pharmaceutical Industry:
(R)-Amino-(4-hydroxyphenyl)acetic acid methyl ester hydrochloride is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a key component in the development of new drugs with specific therapeutic properties.
Used in Antiviral Applications:
In the pharmaceutical industry, (R)-Amino-(4-hydroxyphenyl)acetic acid methyl ester hydrochloride is used as a building block for the production of antiviral peptides. These peptides have the potential to inhibit viral replication and protect cells from viral infections.
Used in Antibiotic Production:
(R)-Amino-(4-hydroxyphenyl)acetic acid methyl ester hydrochloride is also utilized in the production of beta-lactam antibiotics, which are a class of antibiotics known for their effectiveness against a wide range of bacterial infections. (R)-Amino-(4-hydroxyphenyl)acetic acid methyl ester hydrochloride's structure contributes to the development of new antibiotics with improved properties, such as enhanced stability and broader spectrum of activity.

InChI:InChI=1/C9H11NO3.ClH/c1-13-9(12)6-10-7-2-4-8(11)5-3-7;/h2-5,10-11H,6H2,1H3;1H

Upstream product

• 67-56-1 methanol 
• 22818-40-2 D-4-hydroxyphenylglycine 
• 37763-23-8 D-2-p-hydroxyphenylglycine methyl ester 

Downstream Products

• 115142-79-5 N-(2-methylcinnamylidene)-α-p-hydroxyphenylglycine methyl ester 
• 189815-93-8 (R)-N-[α-(methoxycarbonyl)-4-hydroxybenzyl]-2-phenylquinoline-4-carboxamide 
• 143323-49-3 (R)-methyl 2-((tert-butoxycarbonyl)amino)-2-(4-hydroxyphenyl)acetate 
• 1005002-02-7 (R)-2-amino-2-(4-hydroxyphenyl)-1,1-diphenylethanol 
• 600738-20-3 4-tert-butoxy-R-phenylglycinol 
• 600738-19-0 N-benzyloxycarbonyl-4-tert-butoxy-R-phenylglycinol 
• 600738-17-8 N-benzyloxycarbonyl-4-tert-butoxy-R-phenylglycine methyl ester 
• 600738-18-9 N-benzyloxycarbonyl-4-tert-butoxy-R-phenylglycine 
• 1042907-20-9 C₄₀H₃₉Cl₂IN₄O₁₁ 
• 1195785-28-4 C₂₄H₂₈FN₃O₈ 
• 1287286-67-2 (S)-N-{(R)-1-[4-((S)-2-methyl-butoxy)-phenyl]-2-propylamino-ethyl}-2-phenyl-propionamide 
• 1286280-72-5 tert-butyl (1R)-2-hydroxy-1-[4-(2-methylpentyloxy)phenyl]ethylcarbamate 
• 1287285-87-3 t-butyl (1R)-2-hydroxy-2-methyl-1-(4-(2-methylpentyloxy)phenyl)-propylcarbamate 
• 1287285-92-0 (1R)-1-amino-2-methyl-1-(4-(2-methylpentyloxy)phenyl)propan-2-ol trifluoroacetate 

Relevant academic research and scientific papers

Preparation method of (-) - Cytoxazone and (+) -4 - epi-Cytoxazone

The preparation method of (-) - Cytoxazone and (+) -4 - epi-Cytoxazone takes D - p-hydroxyphenylglycine as a raw material, the intermediate 2 is obtained through methyl esterification reaction under catalysis of thionyl chloride, and then the amino is protected with Boc anhydride to obtain the intermediate 3. The compound 4 is obtained by using potassium carbonate as a base and reacting with methyl iodide under reflux conditions. The methyl ester was reduced with sodium borohydride/lithium chloride to give the primary alcohol compound 5. An intermediate IBX is then obtained with 6 primary alcohol, then reacted with acetone cyanohydrin SN2 to give intermediate 7, and the intermediate 8 is obtained by reacting with the methanol solution of hydrogen chloride to obtain two five-membered ring compound compounds 9 and 10, respectively, with sodium borohydride to obtain (-) - Cytoxazone and its isomers (+) -4 - epi-Cytoxtoxtoxtoxol, respectively.

Compound, pharmaceutically acceptable salt thereof and medical application thereof

The invention belongs to the field of medicines, and particularly relates to a compound shown as a formula I or medicinal salt thereof. The invention also relates to application of the compound or themedicinal salt thereof in selectively inhibiting LF activity, resisting anthrax toxin toxicity and preventing or treating anthracnose.

Intermediate of RORgamma inhibitor and preparation method thereof

The invention belongs to the technical field of drugs, in particular to an intermediate of a RORgamma inhibitor and a preparation method thereof. The intermediate is as shown in a formula (I). The method has the advantages of being easily available in raw material, concise in process, economic and environment-friendly, high in yield and the like. The formula is as shown in the description.

((S)-3-Mercapto-2-methylpropanamido)acetic acid derivatives as metallo-β-lactamase inhibitors: Synthesis, kinetic and crystallographic studies

The emergence and global spread of metallo-β-lactamase (MBL) mediated resistance to almost all β-lactam antibacterials poses a serious threat to public health. Since no clinically useful MBL inhibitors have been reported, there is an urgent need to develop new potent broad-spectrum MBL inhibitors effective against antibacterial resistance. Herein, we synthesized a set of 2-substituted ((S)-3-mercapto-2-methylpropanamido) acetic acid derivatives, some of which displayed potent inhibition with high ligand efficiency to the clinically relevant MBL subtypes, Verona Integron-encoded MBL (VIM)-2 and New Delhi MBL (NDM)-1. Kinetic studies revealed that the inhibitors are not strong zinc chelators in solution, and they bind reversibly to VIM-2 but dissociate very slowly. Crystallographic analyses revealed that they inhibit VIM-2 via chelating the active site zinc ions and interacting with catalytically important residues. Further cell- and zebrafish-based assays revealed that the inhibitors slightly increase susceptibility of E. coli cells expressing VIM-2 to meropenem, and they have no apparent toxicity to the viability of HEK293T cells and the zebrafish embryogenesis.

NOVEL ANTIESTROGENIC HETEROCYCLIC COMPOUNDS

The present invention provides novel heterocyclic compounds of Formula I wherein A, B, E, ring Z, Y, L, ring X, D, m, n, R7 and R8 are as defined in the specification as estrogen receptor antagonists/degraders. The compound of Formula I can be used for the treatment of cancers mediated by estrogen receptors. (Formula I ).

Electronic effects of aryl-substituted bis(oxazoline) ligands on the outcome of asymmetric copper-catalysed C-H insertion and aromatic addition reactions

The effect of the modification of bis(oxazoline) ligands on the outcome of copper-catalysed C-H insertion and aromatic addition reactions is described. In general, these reactions display minimum sensitivity in terms of enantiocontrol to variation of the electronic properties of the aryl moiety of the ligand however, some influence is observed for C-H insertions employing naphthyl-substituted bis(oxazolines) and for aromatic addition reactions of biphenyl diazo ketone substrates. The synthesis of the modified bis(oxazolines), which include four novel structures, is also described.

A multikilogram-scale synthesis of (R)-methyl 2-[(1r,4R)-4-(tert-butoxy- carbonylamino)cyclohexyl]-2-(2-nitrophenylsulfonamido)acetate - A doubly protected building block with three points of variation

A robust and scalable synthesis of (R)-methyl 2-[(1r,4R)-4-(tert- butoxycarbonylamino)cyclohexyl]-2-(2-nitrophenylsulfon-amido)acetate is reported. This serves as a scaffold for the preparation of trans-substituted aminocyclohexanes. The key synthetic step is the reduction of d-4-hydroxyphenylglycine, or a protected equivalent, to achieve the required regiochemistry across the cyclohexyl ring. Georg Thieme Verlag Stuttgart · New York.

Synthesis and bioactivity of some 2-oxo-5-aryl-3-hydrazone and 2-oxo-5-aryl-4-hydrazone pyrrolidine derivatives

2-Aryl-4,5-dioxopyrrolidine-3-carboxylate and 5-aryl-2,4-dioxopyrrolidine- 3-carboxylate derivatives were successfully synthesized via carbonyl-based multiple component reaction and Dieckmann cyclization, respectively. Successive functional group transformations which include decarboxylation and hydrazonation afforded 2-oxo-5-aryl-3-hydrazone and 2-oxo-5-aryl-4-hydrazone derivatives. Compound 3d exhibited activity against human histiocytic lymphoma (U937) and neuroblastoma (SH-SY5Y) cell lines while compound 6 showed neuroprotective ability from oxidative stress medium induced with H2O2.

Synthesis of hydroxyphenylglycine-derived novel poly(silylenevinylenephenyleneethynylene)s

The hydrosilylation polymerization of d-(-)-p-hydroxyphenylglycine-derived diethynyl monomers 1p and 1m with dihydrosilanes Si1 and Si2 was carried out using RhI(PPh3)3 as a catalyst to give optically active novel poly(silylenevinylenephenyleneethynylene)s [(E)-poly(1p-Si1), (E)-poly(1p-Si2), (E)-poly(1m-Si1), (E)-poly(1m-Si2), and (Z)-poly(1p-Si1)] with number-average molecular weights ranging from 2800 to 17,000 in 41-92% yields. Polymers having (E)- and (Z)-olefin moieties were obtained, wherein the (E)-/(Z)-ratios depended on the reaction conditions. The UV-vis absorption edge of (E)-poly(1p-Si1) was positioned at a wavelength longer than that of (Z)-poly(1p-Si1), indicating that (E)-vinylene-linkage extends the conjugation more largely than the (Z)-counterpart. This was also confirmed by fluorescence spectroscopy. Alkaline hydrolysis of ester moieties of these polymers gave the corresponding polymers having carboxy groups. The (E)-polymers showed different solubility in hydrophobic solvents before and after hydrolysis, but the non-hydrolyzed and hydrolyzed (Z)-polymers exhibited the same solubility.

Diketopiperazine supramolecule derived from hydroxyphenylglycine

A diketopiperazine (DKP) having long alkyl chains was synthesized from D-p-hydroxyphenylglycine, and the formation of supramolecules was examined. The 1H NMR and UV-vis spectroscopic measurements and molecular modeling have suggested that the D